Everolimus
Orphan DrugFDA Approved
Description
Everolimus is a kinase inhibitor used in the treatment of kidney clear cell carcinoma. It works by inhibiting mTOR, a protein that regulates cell growth and proliferation. Everolimus is available as an oral tablet.
Indications & Therapeutic Use
Kidney clear cell sarcoma
Global Availability (5 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
Everolimus
| Generic Name | Everolimus |
| Brands | 1 brand available |
| Active Ingredient | Everolimus |
| Drug Class | Kidney clear cell sarcoma |
| Manufacturer | Novartris |
| Dosage Forms | Oral tablet |
| Medical Code | L01EH01 |
| Orphan Status | Yes — Orphan Drug |
| Cold Chain | Not Required |
| Reg. Status | FDA Approved |
| Countries | 5 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations6 Validated Nodes